181 related articles for article (PubMed ID: 37738997)
1. Primary brain tumours in adults.
van den Bent MJ; Geurts M; French PJ; Smits M; Capper D; Bromberg JEC; Chang SM
Lancet; 2023 Oct; 402(10412):1564-1579. PubMed ID: 37738997
[TBL] [Abstract][Full Text] [Related]
2. The prognostic value of clinical factors and cancer stem cell-related markers in gliomas.
Dahlrot RH
Dan Med J; 2014 Oct; 61(10):B4944. PubMed ID: 25283629
[TBL] [Abstract][Full Text] [Related]
3. A contemporary perspective on the diagnosis and treatment of diffuse gliomas in adults.
Roth P; Hottinger AF; Hundsberger T; Läubli H; Schucht P; Reinert M; Mamot C; Roelcke U; Pesce G; Hofer S; Weller M
Swiss Med Wkly; 2020 Jun; 150():w20256. PubMed ID: 32557428
[TBL] [Abstract][Full Text] [Related]
4. Tumour immune landscape of paediatric high-grade gliomas.
Ross JL; Velazquez Vega J; Plant A; MacDonald TJ; Becher OJ; Hambardzumyan D
Brain; 2021 Oct; 144(9):2594-2609. PubMed ID: 33856022
[TBL] [Abstract][Full Text] [Related]
5. Primary brain tumours in adults.
Lapointe S; Perry A; Butowski NA
Lancet; 2018 Aug; 392(10145):432-446. PubMed ID: 30060998
[TBL] [Abstract][Full Text] [Related]
6. Management of diffuse low-grade gliomas in adults - use of molecular diagnostics.
Buckner J; Giannini C; Eckel-Passow J; Lachance D; Parney I; Laack N; Jenkins R
Nat Rev Neurol; 2017 Jun; 13(6):340-351. PubMed ID: 28497806
[TBL] [Abstract][Full Text] [Related]
7. Targeted next-generation sequencing of adult gliomas for retrospective prognostic evaluation and up-front diagnostics.
Petersen JK; Boldt HB; Sørensen MD; Blach S; Dahlrot RH; Hansen S; Burton M; Thomassen M; Kruse T; Poulsen FR; Andreasen L; Hager H; Ulhøi BP; Lukacova S; Reifenberger G; Kristensen BW
Neuropathol Appl Neurobiol; 2021 Feb; 47(1):108-126. PubMed ID: 32696543
[TBL] [Abstract][Full Text] [Related]
8. Glioma.
Weller M; Wick W; Aldape K; Brada M; Berger M; Pfister SM; Nishikawa R; Rosenthal M; Wen PY; Stupp R; Reifenberger G
Nat Rev Dis Primers; 2015 Jul; 1():15017. PubMed ID: 27188790
[TBL] [Abstract][Full Text] [Related]
9. The 2016 revision of the WHO Classification of Central Nervous System Tumours: retrospective application to a cohort of diffuse gliomas.
Rogers TW; Toor G; Drummond K; Love C; Field K; Asher R; Tsui A; Buckland M; Gonzales M
J Neurooncol; 2018 Mar; 137(1):181-189. PubMed ID: 29218432
[TBL] [Abstract][Full Text] [Related]
10. Advances in Immune Microenvironment and Immunotherapy of Isocitrate Dehydrogenase Mutated Glioma.
Yan D; Li W; Liu Q; Yang K
Front Immunol; 2022; 13():914618. PubMed ID: 35769466
[TBL] [Abstract][Full Text] [Related]
11. Clinical importance of molecular markers of adult diffuse glioma.
Molinari E; Curran OE; Grant R
Pract Neurol; 2019 Oct; 19(5):412-416. PubMed ID: 31175262
[TBL] [Abstract][Full Text] [Related]
12. Deciphering diffuse glioma immune microenvironment as a key to improving immunotherapy results.
Picca A; Finocchiaro G
Curr Opin Oncol; 2022 Nov; 34(6):653-660. PubMed ID: 36000367
[TBL] [Abstract][Full Text] [Related]
13. Advances in the Immunotherapeutic Potential of Isocitrate Dehydrogenase Mutations in Glioma.
Tang F; Pan Z; Wang Y; Lan T; Wang M; Li F; Quan W; Liu Z; Wang Z; Li Z
Neurosci Bull; 2022 Sep; 38(9):1069-1084. PubMed ID: 35670952
[TBL] [Abstract][Full Text] [Related]
14. Neurological update: gliomas and other primary brain tumours in adults.
Brandner S; Jaunmuktane Z
J Neurol; 2018 Mar; 265(3):717-727. PubMed ID: 29098416
[TBL] [Abstract][Full Text] [Related]
15. Implications of IDH mutations on immunotherapeutic strategies for malignant glioma.
Richardson LG; Miller JJ; Kitagawa Y; Wakimoto H; Choi BD; Curry WT
Neurosurg Focus; 2022 Feb; 52(2):E6. PubMed ID: 35104795
[TBL] [Abstract][Full Text] [Related]
16. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
[TBL] [Abstract][Full Text] [Related]
17. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
[TBL] [Abstract][Full Text] [Related]
18. BRAF V600E-mutated diffuse glioma in an adult patient: a case report and review.
Suzuki Y; Takahashi-Fujigasaki J; Akasaki Y; Matsushima S; Mori R; Karagiozov K; Joki T; Ikeuchi S; Ikegami M; Manome Y; Murayama Y
Brain Tumor Pathol; 2016 Jan; 33(1):40-9. PubMed ID: 26445861
[TBL] [Abstract][Full Text] [Related]
19. Characteristics of IDH-mutant gliomas with non-canonical IDH mutation.
Poetsch L; Bronnimann C; Loiseau H; Frénel JS; Siegfried A; Seizeur R; Gauchotte G; Cappellen D; Carpentier C; Figarella-Branger D; Eimer S; Meyronet D; Ducray F;
J Neurooncol; 2021 Jan; 151(2):279-286. PubMed ID: 33205355
[TBL] [Abstract][Full Text] [Related]
20. Low FoxG1 and high Olig-2 labelling indices define a prognostically favourable subset in isocitrate dehydrogenase (IDH)-mutant gliomas.
Schäfer S; Behling F; Skardelly M; Koch M; Ott I; Paulsen F; Tabatabai G; Schittenhelm J
Neuropathol Appl Neurobiol; 2018 Feb; 44(2):207-223. PubMed ID: 29053887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
